Swedish Orphan Biovitrum AB (publ) Price, Chart & Factor Exposure
Free Data & Analytics AccessNext earnings: Thu, Feb 4, 2027, after the market closes · estimates and history
Swedish Orphan Biovitrum AB (publ) Forecast
Swedish Orphan Biovitrum AB (publ) short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 25.5% a year, a typical one-standard-deviation range is 461.97–496.43 over a week, 443.89–514.51 over a month and 356.87–601.53 over a year. (Signals as of 5 Nov 2026.)
Swedish Orphan Biovitrum AB (publ) Price Chart
Swedish Orphan Biovitrum AB (publ) Factors
YoY −99.7%
YoY +27.6%
YoY +16.1%
YoY +12.2%
YoY +25.4%
YoY −27.7%
YoY +34,691.7%
YoY +46.5%
YoY +20.7%
YoY −5.9%
YoY −2.6%
YoY −5.4%
YoY −5.8%
YoY 0.0%
YoY +20.5%
Swedish Orphan Biovitrum AB (publ) fundamentals: income statement, balance sheet & cash flow
Swedish Orphan Biovitrum AB (publ) reported revenue of 28.24bn SEK and net income of 478.0m SEK in FY2025, the year ended 31 December 2025 — revenue up 8.5% and net income down 87.7% on the prior year. Free cash flow was 8.52bn SEK. These figures are as reported in the filings, not restated: 24 fiscal years and 71 quarters of history, back to December 2002.
| SEK billions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 28.24 | 26.03 | 22.12 | 18.79 | 15.53 |
| Cost of revenue | 15.92 | 5.79 | 12.18 | 4.81 | 3.48 |
| Gross profit | 12.32 | 20.24 | 9.95 | 13.98 | 12.05 |
| Research & development | 3.25 | 3.54 | 2.80 | 2.35 | 1.99 |
| Selling, general & admin. | 1.02 | — | 3.09 | 7.85 | 6.29 |
| Operating income | 8.05 | 5.63 | 4.07 | 3.81 | 3.73 |
| EBITDA | 10.96 | 9.30 | 7.23 | 6.05 | 5.72 |
| Interest expense | 0.83 | 1.24 | 1.11 | 0.46 | 0.42 |
| Pre-tax income | 0.03 | 4.41 | 2.95 | 3.32 | 3.30 |
| Income tax | -0.44 | 0.53 | 0.55 | 0.68 | 0.62 |
| Net income | 0.48 | 3.89 | 2.41 | 2.64 | 2.68 |
Download Swedish Orphan Biovitrum AB (publ) fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.SOBI.ST&statement=all&freq=a&format=csv&years=10
Figures in SEK, statements as filed. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic.
Research on Swedish Orphan Biovitrum AB (publ)
Explore MacroFinance macro & markets research and analysis.
Swedish Orphan Biovitrum AB (publ) Trading Strategies
9 backtested tactical asset allocation strategies hold VGK (European market), the closest tradable exposure to Swedish Orphan Biovitrum AB (publ); 1 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in VGK | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Adaptive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Defensive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Protective Asset Allocation - CPR | Moderate | Monthly | Premium · upgrade to view | |||
| Financial Mentor's Optimum3 | Moderate | Monthly | Premium · upgrade to view | |||
| Wouter Keller's Bold Asset Allocation - Balanced | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Protective Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Vigilant Asset Allocation - Balanced | Moderate | Monthly | Premium · upgrade to view | |||
| Ilya Kipnis' Defensive Adaptive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keuning and Keller's Generalized Protective Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
Statistical Distribution of Returns
PlusHow Swedish Orphan Biovitrum AB (publ)’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Swedish Orphan Biovitrum AB (publ) (Sweden)
Swedish Orphan Biovitrum AB (publ) is a listed security in Sweden. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
Frequently asked questions
What is Swedish Orphan Biovitrum AB (publ)?
What is the latest Swedish Orphan Biovitrum AB (publ) price?
Is Swedish Orphan Biovitrum AB (publ) in an uptrend?
How volatile is Swedish Orphan Biovitrum AB (publ)?
What factors affect Swedish Orphan Biovitrum AB (publ)?
Which trading strategies trade Swedish Orphan Biovitrum AB (publ)?
How are Swedish Orphan Biovitrum AB (publ) returns analysed?
Where can I download free Swedish Orphan Biovitrum AB (publ) historical data?
Free Swedish Orphan Biovitrum AB (publ) historical data (last 10 years)
Browse or instantly download the last 10 years of Swedish Orphan Biovitrum AB (publ) daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.SOBI.ST&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 464 |
| 2026-11-19 | 467.8 |
| 2026-11-18 | 474.2 |
| 2026-11-17 | 472.8 |
| 2026-11-16 | 480.2 |
| 2026-11-13 | 474.2 |
| 2026-11-12 | 487 |
| 2026-11-11 | 485.6 |
| 2026-11-10 | 480.2 |
| 2026-11-09 | 496.6 |
About this stock
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company is in strategic partnership with Innate Pharma SA to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.